TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value

European Journal of Cancer

Volumn 35, Issue 12, 1999, Pages 1683-1687

  Soontrapornchai, P ^a   Elsaleh, H ^a,b   Joseph, D ^b   Hamdorf, J M ^a   House, A K ^a   Iacopetta, B ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Adjuvant therapy; Biopsy; Oesophageal adenocarcinoma; Patient outcome; Prognostic marker; TP53 gene

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; CANCER ADJUVANT THERAPY; ESOPHAGUS CARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS;

EID: 0033393711     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00172-0     Document Type: Article

References (26)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 46:1996;5-27.
2. Blot W.J., Devesa S.S., Fraumeni J.F. Continuing climb in rates of oesophageal adenocarcinoma: an update. J. Am. Med. Assoc. 270:1993;1320.
3. Bessel J.R., Devitt P.G., Gill P.G., Goyal S., Jamieson C.G. Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy. Aust. NZ J. Surg. 66:1996;214-217.
4. Ferguson M.K., Reeder L.B., Hoffman P.C., Haraf D.J., Drinkard L.C., Vokes E.E. Intensive multimodality therapy for carcinoma of the esophagus and gastro-oesophageal junction. Ann. Surg. Oncol. 2:1995;101-106.
5. Walsh T.N., Noonan N., Hollywood D.et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335:1996;462-467.
6. Smithers B.M., Devitt P., Jamieson C.G.et al. A combined modality approach to the management of oesophageal cancer. Eur. J. Surg. Oncol. 23:1997;219-223.
7. Bosari S., Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. A. Pathol. Anat. Histopathol. 427:1995;229-241.
8. Sjogren S., Inganas M., Norberg T.et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88:1996;173-182.
9. Soong R., Iacopetta B., Harvey J.et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int. J. Cancer. 74:1997;642-647.
10. Lim B.G.H., Soong R., Grieu F., Robbins P.D., House A.K., Iacopetta B.J. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int. J. Cancer. 69:1996;200-204.
11. Sarbia M., Porschen R., Borchard F., Horstmann O., Willers R., Gabbert H.E. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 74:1994;2218-2223.
12. Casson A.G., Kerkvliet N., O'Malley F. Prognostic value of p53 protein in oesophageal adenocarcinoma. J. Surg. Oncol. 60:1995;5-11.
13. Muro K., Ohtsu A., Boku N.et al. Association of p53 protein expression with responses and survival of patients with locally advanced oesophageal carcinoma treated with chemoradiotherapy. Jpn. J. Clin. Oncol. 26:1996;65-69.
14. Sauter E.R., Keller S.M., Erner S.M. p53 correlates with improved survival in patients with oesophageal carcinoma. J. Surg. Oncol. 58:1995;269-273.
15. Duhaylongsod F.G., Gottfried M.R., Iglehart J.D., Vaughn A.L., Wolfe W.G. The significance of c-erb B2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann. Surg. 221:1995;677-684.
16. Uchino S., Saito T., Inomata M.et al. Prognostic significance of the p53 mutation in oesophageal cancer. Jpn. J. Clin. Oncol. 26:1996;287-292.
17. Coggi G., Bosari S., Roncalli M.et al. p53 protein accumulation and p53 gene mutation in oesophageal carcinoma. a molecular and immunohistochemical study with clinicopathological correlations Cancer. 79:1997;425-432.
18. Casson A.G., Tammemagi M., Eskandarian S., Redston M., McLaughlin J., Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. J. Clin. Pathol.: Mol. Pathol. 51:1998;71-79.
19. Ribeiro U., Finkelstein S.D., Safatle-Ribeiro A.V.et al. p53 sequence analysis predicts treatment response and outcome of patients with oesophageal carcinoma. Cancer. 83:1998;7-18.
20. Sobin L.H., Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours. 5th edn. 1997;Springer, Berlin.
21. Dix B., Robbins P., Carrello S., House A., Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer. 70:1994;585-590.
22. Schneider P.M., Casson A.G., Levin B.et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J. Thoracic. Cardiovasc Surg. 111:1996;323-331.
23. Gleeson C.M., Sloan J.M., McManus D.T.et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br. J. Cancer. 77:1998;277-286.
24. Soong R., Knowles S., Williams K.E., Hammond I.G., Wysocki S., Iacopetta B. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer. 74:1996;562-567.
25. Soong R., Grieu F., Robbins P.et al. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer. Res. 3:1997;1405-1411.
26. Ikeguchi M., Saito H., Katano K.et al. Radiochemosensitivity and expression of p53 in patients with oesophageal cancer treated by absolute noncurative resection. Anticancer Res. 18:1998;493-497.